期刊
CURRENT MEDICAL SCIENCE
卷 41, 期 3, 页码 491-497出版社
SPRINGER
DOI: 10.1007/s11596-021-2377-3
关键词
all-trans retinoic acid; acute promyelocytic leukemia; arsenic trioxide; anthracycline; internal tandem duplication of FMS-like tyrosine kinase 3
This study analyzed the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA, IDA, and/or ATO. The results showed that ATRA plus ATO and anthracycline-based chemotherapy achieved great outcomes in newly diagnosed APL patients, regardless of FLT3-ITD mutation status.
All-trans retinoic acid (ATRA) and pre-upfront arsenic trioxide (ATO) have revolutionized the therapy of acute promyelocytic leukemia (APL). However, internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations is associated with increased risk of relapse. The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA, idarubicin (IDA) and/or ATO, followed by ATRA plus ATO along with anthracycline, as consolidation therapy. A total of 72 patients newly diagnosed with APL were included in this study. 83.3% of the patients achieved complete remission (CR) after induction therapy. FLT3-ITD mutations were detected in 16 (22.2%) patients and closely related to bcr-3 PML-RARa transcript (P<0.001). The 5-year overall survival (OS) rate was 100% in both FLT3-ITDpositive and FLT3-ITDnegative groups, and there was no significant difference in 5-year event-free survival (EFS) between the two groups (78.3% vs. 83.3%, P=0.85). ATRA plus ATO and anthracycline-based chemotherapy achieved great outcome in newly diagnosed APL regardless of the FLT3-ITD mutation status.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据